image credit: Pexels

Ligand grows in cancer again with $100m Apeiron takeover

July 9, 2024


Qarziba (dinutuximab beta) is on the market in 35 ex-US markets for the treatment of high-risk neuroblastoma in patients aged 12 months and above. It is sold by Recordati in all markets except for China, where BeiGene has rights, with both licensees paying undisclosed royalties.

The deal includes an additional payment to Apeiron shareholders of $28 million if Qarziba royalties exceed a certain threshold by either 2030 or 2034, and is expected to close before the end of the month.

Read More on Pharmaphorum